News
Eisai debuts biliary tract cancer drug in Japan
Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug
Oncology
Inside ESMO 2024: Treatments, trials, and top HCPs on social...
Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.
News
NICE blames companies for breakdown in Enhertu talks
Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.
News
MSD says subcutaneous Keytruda matches IV form
A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
Oncology
Sponsored
12 Questions with Gerhard du Toit
As Global Head of Oncology for IQVIA Biotech, Gerhard du Toit manages all aspects of oncology clinical trials, optimising strategies and enhancing delivery from early to late phases.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
